TrovaGene, Inc. (NASDAQ:TROV) Stake Held by Cvi Investments, Inc.

Cvi Investments, Inc.

recently disclosed that they own a 5.7% stake in TrovaGene, Inc. (NASDAQ:TROV) in a Form 13G disclosure that was filed with the SEC on Monday, July 24th. The investor owns 2,124,250 shares of the stock worth about $1,762,490. The reporting parties listed on the disclosure included CVI Investments, Inc and Heights Capital Management, Inc. The disclosure is available through the SEC website at this hyperlink.

Cvi Investments, Inc.

provided the following explanation of their ownership:

Warning: file_get_contents(): php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Warning: file_get_contents(
): failed to open stream: php_network_getaddresses: getaddrinfo failed: Name or service not known in /home/acctmp/public_html/download.php on line 6

Separately, Two Sigma Securities LLC boosted its stake in shares of TrovaGene by 262.4% in the first quarter. Two Sigma Securities LLC now owns 120,516 shares of the medical research company’s stock valued at $139,000 after buying an additional 87,264 shares during the last quarter. 15.14% of the stock is currently owned by hedge funds and other institutional investors.

Shares of TrovaGene, Inc. (NASDAQ TROV) traded up 2.4321% during mid-day trading on Friday, reaching $0.8297. The company’s stock had a trading volume of 152,366 shares. TrovaGene, Inc. has a 12 month low of $0.61 and a 12 month high of $5.54. The company has a 50 day moving average price of $0.99 and a 200 day moving average price of $1.18. The stock’s market capitalization is $30.92 million.

WARNING: This news story was first posted by BNB Daily and is owned by of BNB Daily. If you are accessing this news story on another publication, it was illegally copied and reposted in violation of US and international trademark & copyright legislation. The correct version of this news story can be accessed at

Several analysts have issued reports on the company. Maxim Group set a $4.00 price objective on TrovaGene and gave the company a “buy” rating in a research note on Wednesday. Cantor Fitzgerald restated an “overweight” rating on shares of TrovaGene in a research note on Tuesday, August 8th.

About TrovaGene

Trovagene, Inc (TrovaGene) is a molecular diagnostic company. The Company focuses on the development and commercialization of a molecular diagnostic technology for use in disease detection and monitoring across a range of medical disciplines. Its primary internal focus is to leverage its cell-free molecular diagnostic platform to facilitate improvements in the field of oncology, while its external focus includes entering into license agreements or collaborations to develop its technology in areas, such as infectious disease, transplant medicine and prenatal genetics.

Institutional Ownership by Quarter for TrovaGene (NASDAQ:TROV)

Receive News & Ratings for TrovaGene Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TrovaGene Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply